论文部分内容阅读
美国科学家已确定两种免疫指标,即在规定时刻的纯 CD_4细胞数和β_2微球蛋白浓度的变化,在临床试验中它们可作为艾滋病人应用抗逆转录病毒药物的替代终点的指标。美国的一项研究,在90名艾滋病或艾滋病相关综合征患者身上,试验了叠氮胸苷(zidovudine)对于五种潜在替代指标的作用,这些指标是指CD_4计数,P24抗原和抗体的血清浓度,β_2微球蛋白,新蝶呤(neopterin,一种免疫指标)的变化。对病人跟踪观察两年或直到去世。用 zidovudine 治疗8~12周后,证明预测长期存活率的最有效的替代指标是对治疗前CD_4计数进行调整后的 CD_4计数的对数值。对其它试验指标进行多元分析后,发现只有基础β_2微球蛋白和8~12周后β_2微球蛋白之间的增加值是与低存活率独立相关的唯一的其它指标。这意味着 CD_4计数较高和那些经过第一次 zidovudine 治疗8~12周后,而β_2微球蛋
Scientists in the United States have determined two immune parameters, namely changes in the number of pure CD4 cells and concentration of β2 microglobulin at defined times, which can be used as surrogate endpoints for antiretroviral drugs in AIDS patients in clinical trials. A US study examined the effects of zidovudine on five potential surrogate markers in 90 patients with AIDS or AIDS-related syndromes. These indicators were CD4 counts, serum concentrations of P24 antigen and antibodies. , β 2 microglobulin, neopterin (neopterin, an immune index) changes. Follow patients for two years or until they die. After 8 to 12 weeks of treatment with zidovudine, the most effective surrogate marker for prognosticating long-term survival was the logarithm of CD4 count adjusted for pretreatment CD4 counts. After multivariate analysis of other testing indicators, it was found that only the baseline β 2 microglobulin and the increase in β 2 microglobulin after 8 to 12 weeks were the only other indicators that were independently associated with low survival rates. This means that the CD_4 count is higher and those after the first zidovudine treatment 8 to 12 weeks later, while the β_2 microspheres egg